pharmaceutical portfolio management

5.21.2013 Lifecycle Management

Less Is Definitely Not More for Counter-Generics Strategies

By Christie Shilling, Research Analyst We have a running joke among the researchers at Cutting Edge Information.  Many of the key findings from our research can be boiled down to one phrase: Start Early.  Our usual advice for pharmaceutical companies...
 

2.6.2013 New Product Development

Challenges of New Product Planning Groups

No longer can companies wait until Phase 3, or even Phase 2, to begin commercializing their developing brands.  Today, the pharma industry sees increasingly competitive markets and payers who require more convincing before reimbursing products.  Companies must...
 

1.3.2013 Lifecycle Management

The Appeal of Authorized Generics

To combat the era of patent cliffs, pharmaceutical companies have long been planning strategies to extend the lives of their blockbuster drugs.  Some companies look to preserve their spot in the market by introducing new indications and new formulations.  Others...
 

7.31.2012 Pipeline Planning

Portfolio Management an Important Part of Pipeline Planning

The recent news that bapineuzumab, a treatment for Alzheimer’s disease, failed to meet two primary endpoints in a recent Phase III study isn’t great for development partners Pfizer and Johnson & Johnson. The new results show the drug fails to produce clinical...
 

7.26.2012 Lifecycle Management

Counter-Generics Strategies

With patents expiring right and left, pharmaceutical companies are looking for every possible tool to slow revenue losses. Counter-generic strategies are one method to maintain market share, however temporary. Even a period of six months when no generic versions...
 

5.17.2012 Alliance Management

Alliance Management Depends on Transparent Communication, Relationships

By Eric Bolesh, Director of Research In collaborations among pharmaceutical and biotech companies, conflicts inevitably arise — and they can spring from a host of different factors. Here are several of the most common issues that we hear about in...
 

2.21.2012 Biomarkers

The Case for Companion Diagnostics

By Ryan McGuire,Senior Research Analyst The megatrend of personalized medicine gained a significant boost of adrenaline recently as Vertex Pharmaceutical's cystic fibrosis drug, Kalydeco (ivacaftor), earned FDA approval. As with much of personalized medicine's...
 

2.20.2012 Health Economics and Outcomes Research (HEOR)

Communicating the Value of Innovation through Health Economics Analysis

By Shaylyn Pike,Senior Research Analyst Once upon a time, a brand team's quest ended at marketing approval; revenues would take care of themselves. Fast forward 20 years, and the industry faces a much more challenging road to brand success. Receiving...
 

1.3.2012 Lifecycle Management

Pfizer Aims to Retain Lipitor Patients for a Little Longer

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...
 

11.28.2011 Lifecycle Management

Top-Performing Lifecycle Management Strategies

By Michelle Vitko,Research Analyst Recently, I wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio....